Marc Wilson - 31 Dec 2024 Form 5 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: CFO
Issuer ticker: CRNX
Reported as of: 31 Dec 2024
Net transaction value: +$7,086
SEC form: 5
Accepted by SEC: 29 Jan 2025, 16:30:04 UTC
Prior SEC filing: 30 Sep 2024
Source filing: View source filing
Reporting owner signature: Marc Wilson, as attorney-in-fact

Key filing fact

Marc Wilson filed Form 5 for Crinetics Pharmaceuticals, Inc. (CRNX) on 29 Jan 2025.

Key facts

This page summarizes Marc Wilson's Form 5 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Jan 2025, 16:30.

Change

Previous filing in this sequence was filed on 30 Sep 2024.
Current net transaction value: +$7,086.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Other

Transaction value: $7,086
Shares: +473
Change %: +0.43%
Price: $14.98
Shares after: 111,565
Date: 20 Nov 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),